Thrombin Inhibitor Market Growth Accelerated by Increasing Preference for Non-invasive Surgeries


 Thrombin inhibitors are drugs used to prevent blood clots by inhibiting thrombin. Thrombin is a serine protease that plays a central role in coagulation as it converts fibrinogen into insoluble strands of fibrin. Thrombin inhibitors are commonly used during surgical procedures to prevent complications associated with thrombus formation. They offer minimal invasiveness, quicker recovery time, and reduce the risk of post-operation complications compared to conventional surgeries. The global Thrombin Inhibitor Market is estimated to be valued at US$ 30.75 billion in 2024 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.


Market key trends: The increasing preference for minimally invasive surgical procedures has been a major factor driving the growth of the thrombin inhibitor market. Minimally invasive surgeries cause less trauma to the patient, result in fewer complications, shorter hospital stay, and quicker recovery time. With growing awareness about these benefits, patients are increasingly opting for surgeries that are less invasive. The adoption of thrombin inhibitors is helping healthcare professionals perform complex surgical procedures through small incisions rather than through open surgery techniques. This trend is expected to continue during the forecast period as more number of surgical procedures adopt minimal invasiveness, thus supporting the demand for thrombin inhibitors.

Segment Analysis
The global thrombin inhibitor market is segmented based on product type, application, end-users and geography. Based on product type, the market is sub-segmented into direct thrombin inhibitors (bivalirudin, argatroban, others) and indirect thrombin inhibitors (warfarin, dabigatran, others). The direct thrombin inhibitors sub-segment dominates the market and is expected to continue its dominance over the forecast period. This is owing to increasing usage of direct thrombin inhibitors for deep vein thrombosis and atrial fibrillation treatments, as they are more predictable and manageable than warfarin.

Key Takeaways
The global thrombin inhibitor market is expected to witness high growth over the forecast period of 2023 to 2030.

Regional analysis: North America dominates the thrombin inhibitor market currently due to the presence of well-established healthcare systems and rising prevalence of cardiac disorders in countries like the US and Canada. Asia Pacific is expected to grow at the fastest rate during the forecast period owing to growing healthcare infrastructure and increasing healthcare investments in developing countries of China and India.

Key players: Key players operating in the thrombin inhibitor market are Pfizer, Bayer, Sanofi, Johnson & Johnson, Merck, Bristol-Myers Squibb, Abbot, Baxter and Boehringer Ingelheim. Pfizer dominates the market with its products Xarelto and Eliquis. Bayer is another leading player with its product Xarelto. 

Comments

Post a Comment

Popular posts from this blog

Unveiling Health Secrets: Exploring the Potential of Blood-Based Biomarkers

Image
  The human body is a complex and intricate system, often harboring subtle signs of its inner workings. One of the most promising avenues for unlocking these secrets lies within our bloodstream – a treasure trove of information encoded in the form of blood-based biomarkers. These biomarkers, measurable indicators present in the blood, hold the potential to revolutionize healthcare by providing early detection, accurate diagnosis, and personalized treatment approaches. Blood-based biomarkers encompass a wide range of molecules – from proteins and nucleic acids to metabolites and even circulating cells. Researchers have been diligently working to identify specific biomarkers associated with various diseases and conditions. For instance, elevated levels of certain proteins might point to cardiovascular diseases, while specific genetic material could indicate the presence of cancer. By analyzing these biomarkers, clinicians gain valuable insights into an individual's health status, en...
Read more

Revolutionizing Biology: Advancements in Single Cell Analysis Techniques

Image
  Single cell analysis has emerged as a groundbreaking technology that is revolutionizing the field of biology. Traditionally, biological studies were conducted on populations of cells, averaging out the heterogeneity present within them. However, the advent of single cell analysis has enabled scientists to delve into the complexity of individual cells, uncovering a wealth of previously inaccessible information. Advancements in single cell analysis techniques have paved the way for a deeper understanding of cellular heterogeneity, gene expression, and cellular behavior. One of the most remarkable techniques is single-cell RNA sequencing (scRNA-seq), which allows scientists to measure gene expression in individual cells. This breakthrough has led to the identification of rare cell types, understanding of cellular communication networks, and the discovery of novel biomarkers. Moreover, single cell imaging techniques, such as single cell fluorescence microscopy, have enabled research...
Read more

Medical Robots Market Poised to Grow Owing to Improving Healthcare Infrastructure

Image
 The Medical Robots Market is anticipated to witness robust growth due to rising healthcare spending across the globe. Medical robots are used to perform minimal invasive surgeries with greater accuracy and flexibility. Growing preference for Robot-Assisted Surgery (RAS) over conventional open surgeries due to benefits such as shorter recovery time and minimum operative scars has been augmenting demand for medical robots. Key functions include guiding and positioning surgical accessories like guide tubes in radiology and guiding catheter and wires in cardiology. With rising chronic disease prevalence associated with aging populations, the need for more surgical procedures is surging which requires precise action minimally invasive robotic systems can provide. The Global Medical Robots Market is estimated to be valued at US$ 11.47 Bn in 2024 and is expected to exhibit a CAGR of 16% over the forecast period 2023 to 2030. Key Takeaways: Key players operating in the Medical Robo...
Read more